AstraZeneca COVID vaccine sales jump to $894 mln, updates forecasts
- United States
AstraZeneca's COVID-19 vaccine sales more than tripled to $894 million in the second quarter from the previous three months but shaved off 1 U.S. cent from earnings, and the drugmaker updated its 2021 forecasts on Thursday to include sales from its Alexion unit.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON: